Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 20, 2024 | June 24, 2024 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| Prime Medicine, Inc.PRME · Entity 5281 | Director | June 05, 2026 | June 08, 2026 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Director | June 18, 2020 | June 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,120 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 2,120 · Balance 2,120 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.45 · Expires 2034-06-20 | Direct | 11,774 |
Reported balance
After 2024-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-20 · Grant · Acquired 11,774 · Balance 11,774 F3: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,665 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 21,665 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F5: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 26,232 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 26,232 F3: The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 31,232 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 31,232 F4: The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.
F4: The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.
F5: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Prime Medicine, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2036-06-05 | Direct | 75,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 603 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 603 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
bluebird bio, Inc.
Report date June 18, 2020 · Filed June 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,832 |
Last balance in matching sequence
After 2020-06-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-06-18 · Grant · Acquired 156 · Balance 5,332 F1: These restricted stock units for common stock vest 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders. Row 2 · 2020-06-18 · Grant · Acquired 1,500 · Balance 6,832 F1: These restricted stock units for common stock vest 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.09 · Expires 2030-06-18 | Direct | 3,000 |
Reported balance
After 2020-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-18 · Grant · Acquired 3,000 · Balance 3,000 F2: This option vests 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units for common stock vest 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders.
F2: This option vests 100% on the earlier of June 18, 2021 or the date of the next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2023 Filed Apr 5, 2023 20:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 16,363 | $9.05 | $148,085.15 |
DisclosureSEC source: 0001439222-23-000058 · wf-form4_168072499813992.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 27, 2023 Filed Mar 30, 2023 01:30 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001439222-23-000056 · wf-form4_168013982720168.xml · derivative · entry 5 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,363 Underlying: Common stock · 20,000 shares Expires 2023-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares. Read SEC document |
| March 27, 2023 Filed Mar 30, 2023 01:30 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 20,000 | $22.15 | $443,000.00 |
DisclosureSEC source: 0001439222-23-000056 · wf-form4_168013982720168.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,879 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $21.93 to $22.36. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 30, 2023 01:30 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 20,000 | $9.05 | $181,000.00 |
DisclosureSEC source: 0001439222-23-000056 · wf-form4_168013982720168.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001439222-23-000055 · wf-form4_167891470531005.xml · derivative · entry 6 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,363 Underlying: Common stock · 20,000 shares Expires 2023-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,667 | $22.72 | $37,874.24 |
DisclosureSEC source: 0001439222-23-000055 · wf-form4_167891470531005.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,879 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $22.67 to $22.81. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 18,333 | $22.47 | $411,942.51 |
DisclosureSEC source: 0001439222-23-000055 · wf-form4_167891470531005.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,546 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $21.67 to $22.66. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 20,000 | $9.05 | $181,000.00 |
DisclosureSEC source: 0001439222-23-000055 · wf-form4_167891470531005.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001439222-23-000041 · wf-form4_167770476285855.xml · derivative · entry 5 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,363 Underlying: Common stock · 20,000 shares Expires 2023-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 20,000 | $25.37 | $507,400.00 |
DisclosureSEC source: 0001439222-23-000041 · wf-form4_167770476285855.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,879 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $25.11 to $25.74. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 20,000 | $9.05 | $181,000.00 |
DisclosureSEC source: 0001439222-23-000041 · wf-form4_167770476285855.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001439222-23-000020 · wf-form4_167649497047928.xml · derivative · entry 5 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,363 Underlying: Common stock · 20,000 shares Expires 2023-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 20,000 | $28.62 | $572,400.00 |
DisclosureSEC source: 0001439222-23-000020 · wf-form4_167649497047928.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,879 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $28.25 to $28.94. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 20,000 | $9.05 | $181,000.00 |
DisclosureSEC source: 0001439222-23-000020 · wf-form4_167649497047928.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001439222-23-000010 · wf-form4_167528545373635.xml · derivative · entry 6 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,363 Underlying: Common stock · 20,000 shares Expires 2023-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,300 | $29.88 | $98,604.00 |
DisclosureSEC source: 0001439222-23-000010 · wf-form4_167528545373635.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,879 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $29.71 to $30.32. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 16,700 | $29.22 | $487,974.00 |
DisclosureSEC source: 0001439222-23-000010 · wf-form4_167528545373635.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,179 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $28.69 to $29.69. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 20,000 | $9.05 | $181,000.00 |
DisclosureSEC source: 0001439222-23-000010 · wf-form4_167528545373635.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001439222-23-000008 · wf-form4_167416220784481.xml · derivative · entry 6 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,363 Underlying: Common stock · 20,000 shares Expires 2023-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,034 | $29.49 | $30,492.66 |
DisclosureSEC source: 0001439222-23-000008 · wf-form4_167416220784481.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,879 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $29.42 to $29.65. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 18,966 | $28.82 | $546,600.12 |
DisclosureSEC source: 0001439222-23-000008 · wf-form4_167416220784481.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,913 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $28.42 to $29.39. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 20,000 | $9.05 | $181,000.00 |
DisclosureSEC source: 0001439222-23-000008 · wf-form4_167416220784481.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 29,307 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001439222-22-000066 · wf-form4_165601510092788.xml · derivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,307 Underlying: Common stock · 29,307 shares Expires 2032-06-21 F3 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock unit · Derivative | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000066 · wf-form4_165601510092788.xml · derivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,975 Underlying: Common stock · 4,975 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,959 | $0.00 Strike: $24.27 | $0.00 |
DisclosureSEC source: 0001714899-22-000098 · wf-form4_165456058126311.xml · derivative · entry 4 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,959 Underlying: Common Stock · 17,959 shares Expires 2032-06-02 F5 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000098 · wf-form4_165456058126311.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,313 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock unit · Derivative | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000051 · wf-form4_165342307618924.xml · derivative · entry 4 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: There restricted stock units were granted on May 20, 2021. The shares underlying these restricted stock units vest as to 100% of the underlying shares on May 20, 2022. F4 · derivative.expiration_date: There restricted stock units were granted on May 20, 2021. The shares underlying these restricted stock units vest as to 100% of the underlying shares on May 20, 2022. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000051 · wf-form4_165342307618924.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000015 · wf-form4_164565054852931.xml · derivative · entry 5 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 758 | $29.08 | $22,042.64 |
DisclosureSEC source: 0001439222-22-000015 · wf-form4_164565054852931.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,294 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000015 · wf-form4_164565054852931.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 6,222 | $0.00 Strike: $63.76 | $0.00 |
DisclosureSEC source: 0001209191-21-038390 · doc4.xml · derivative · entry 4 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 Underlying: Common Stock · 6,222 shares Expires 2031-06-02 F4 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 2,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038390 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,327 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038047 · doc4.xml · derivative · entry 4 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F4 · derivative.expiration_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038047 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000050 · wf-form4_162266441654458.xml · derivative · entry 4 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000050 · wf-form4_162266441654458.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 8,888 | $0.00 Strike: $56.76 | $0.00 |
DisclosureSEC source: 0001439222-21-000046 · wf-form4_162188910802212.xml · derivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common stock · 8,888 shares Expires 2031-05-20 F3 · derivative.exercise_date: This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock unit · Derivative | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000046 · wf-form4_162188910802212.xml · derivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,585 Underlying: Common stock · 1,585 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested F2 · derivative.expiration_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000022 · wf-form4_161420115567750.xml · derivative · entry 5 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,775 Underlying: Common stock · 2,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 821 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000022 · wf-form4_161420115567750.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,591 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000022 · wf-form4_161420115567750.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000009 · wf-form4_161359634798927.xml · derivative · entry 5 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 8,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 2,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000009 · wf-form4_161359634798927.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,638 Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000009 · wf-form4_161359634798927.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 24, 2020 02:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,000 | $90.01 | $450,027.00 |
DisclosureSEC source: 0001209191-20-065134 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 26,232 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average price of the shares sold ranging from $90.00 to $90.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · balance_after: This number is restated pursuant to an internal review of the Reporting Person's holdings, and reflects the consolidation of shares between trusts associated with the Reporting Person. F5 · ownership.nature: The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 21, 2020 Filed Dec 24, 2020 02:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 25,000 | $90.06 | $2,251,555.00 |
DisclosureSEC source: 0001209191-20-065134 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average price of the shares sold ranging from $90.00 to $90.38 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 22:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 30,000 | $70.05 | $2,101,590.00 |
DisclosureSEC source: 0001209191-20-058334 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.00 to $70.305 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,000 | $60.03 | $600,310.00 |
DisclosureSEC source: 0001209191-20-057936 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:53 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,000 | $50.18 | $501,830.00 |
DisclosureSEC source: 0001209191-20-057336 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.00 to $50.71 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.